News from the FDA/CDC

COPD rates reflect current smoking prevalence


 

FROM MMWR

Chronic obstructive pulmonary disease (COPD) prevalence among adults is strongly correlated with their state’s current smoking prevalence, according to a Centers for Disease Control and Prevention analysis of respondents to a behavioral risk factor survey.

“Population-based strategies for smoking prevention and control have the potential to decrease the prevalence of COPD in the United States,” wrote Anne G. Wheaton, PhD, of the CDC’s National Center for Chronic Disease Prevention and Health Promotion and coauthors. The study was published in the Morbidity and Mortality Weekly Report.

Dr. Wheaton and her fellow researchers analyzed data from 418,378 adult respondents to the 2017 Behavioral Risk Factor Surveillance System survey. Responses came from all 50 states and Washington, D.C.; respondents who had smoked less than 100 lifetime cigarettes were categorized as “never smoked,” while those who had smoked at least 100 cigarettes but no longer smoked were categorized as “former smokers.” Anyone who had smoked at least 100 cigarettes and currently smoked was categorized as a “current smoker.”

The age-adjusted prevalence of COPD among U.S. adults was 6.2% (95% confidence interval, 6.0%-6.3%) in 2017. Current cigarette smokers had a prevalence of 15.2% (95% CI, 14.7%-15.7%); this dipped to 7.6% (95% CI, 7.3%-8.0%) among former smokers and 2.8% (95% CI, 2.7%-2.9%) among adults who had never smoked. Patterns were visible within states: Current smokers had a state-level prevalence of COPD that was strongly correlated with state-level current smoking prevalence (Pearson correlation coefficient, 0.69; P less than .001). State-level COPD prevalence among former smokers (Pearson correlation coefficient, 0.71; P less than .001) and those who never smoked (Pearson correlation coefficient, 0.64; P less than .001) were also strongly correlated with the current smoking prevalence, indicating secondhand smoke as a risk factor for COPD.

The coauthors acknowledged the study’s limitations, including relying on self-reporting for both COPD and smoking status. They also noted that there was no way to measure exposure to secondhand smoke, other indoor or outdoor air pollutants, or respiratory infection history, “all of which might contribute to COPD risk.”

No conflicts of interest were reported.

SOURCE: Wheaton AG et al. MMWR Morb Mortal Wkly Rep. 2019 Jun 21;68(24):533-8.

Recommended Reading

E-cigarettes beat nicotine patch for smoking cessation
MDedge Internal Medicine
Poor COPD management might increase MI risk in HIV
MDedge Internal Medicine
Daily aspirin associated with lower risk of COPD flareup
MDedge Internal Medicine
Abatacept appears safe for RA patients with COPD
MDedge Internal Medicine
Pulmonologist: In COPD, try dual therapy before adding corticosteroid
MDedge Internal Medicine
No raised risk of cardiovascular events for COPD patients on aclidinium
MDedge Internal Medicine
AFib on the rise in end-stage COPD patients hospitalized for exacerbations
MDedge Internal Medicine
Eosinophil-guided therapy reduces corticosteroid use in COPD
MDedge Internal Medicine
COPD exacerbations associated with poor sleep quality
MDedge Internal Medicine
Nicotine replacement therapy beats varenicline for smokers with OUD
MDedge Internal Medicine